Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon alpha kinoid - Neovacs

Drug Profile

Interferon alpha kinoid - Neovacs

Alternative Names: Antiferon; IFNalpha kinoid vaccine - Neovacs; IFNα-kinoid

Latest Information Update: 19 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neovacs
  • Developer Department Immunology of Diabetes at Hospital Cochin; Neovacs; sanofi pasteur
  • Class Antihyperglycaemics; Interferons; Recombinant fusion proteins; Skin disorder therapies; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Dermatomyositis; Systemic lupus erythematosus

Highest Development Phases

  • Phase II Dermatomyositis; Systemic lupus erythematosus
  • Preclinical Type 1 diabetes mellitus
  • Discontinued HIV infections; Sjogren's syndrome

Most Recent Events

  • 07 Jun 2019 Immunogenicity data from preclinical studies in Type 1 diabetes mellitus presented at the 79th Annual Scientific Sessions of the American Diabetes Association (ADA-2019)
  • 25 Mar 2019 Neovacs has patent protection for Interferon alpha kinoid and its application in China and Russia
  • 25 Mar 2019 NeoVacs plans a phase III trial for Systemic lupus erythematosus in USA and Europe (IM) in 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top